Synergy Pharmaceuticals Reports First Quarter 2014 Financial Results: Cash And Investments Increase To $70.6 Million As Of March 31, 2014
5/13/2014 7:14:53 AM
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today reported its financial results and business update for the first quarter ended March 31, 2014. Synergy is developing plecanatide for the treatment of both chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), plus SP-333 for opioid-induced constipation (OIC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by